Literature DB >> 17938800

Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry.

Conxita Falgá1, Josep Antón Capdevila, Silvia Soler, Ramón Rabuñal, Juan Francisco Sánchez Muñoz-Torrero, Pedro Gallego, Manuel Monreal.   

Abstract

There is little information on the clinical outcome of patients with venous thromboembolism and renal insufficiency. RIETE is an ongoing, prospective registry of consecutive patients with acute, objectively confirmed, symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE). In this analysis we analyzed the three-month outcome in patients with creatinine clearance (CrCl) <30 ml/min. As of March 2007, 1,037 of the 18,251 (5.7%) patients enrolled in RIETE had CrCl <30 ml/min. During the three-month study period these patients had an increased incidence of fatal bleeding, fatal PE, and overall death compared to those with CrCl >30 ml/min. Of the 579 patients presenting with clinically overt PE, 52 (9.0%) died of the initial PE, 13 (2.2%) of recurrent PE, and nine (1.6%) died of bleeding complications. During the first 15 days of therapy the 10% incidence of fatal PE was 10-fold their 1.0% of fatal bleeding. From day 16 to 90, the 1.0% rate of fatal PE was not significantly higher than the 0.5% of fatal bleeding. Of the 458 DVT patients with CrCl <30 ml/min, 14 (3.1%) had fatal bleeding and only one (0.2%) died of PE. In patients with CrCl <30 ml/min presenting with clinically overt PE the main threat is PE itself. On the contrary, in those with DVT the main threat is bleeding.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938800

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.

Authors:  Dagmar Kubitza; Michael Becka; Wolfgang Mueck; Atef Halabi; Haidar Maatouk; Norbert Klause; Volkmar Lufft; Dominic D Wand; Thomas Philipp; Heike Bruck
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Development of atrial fibrillation in patients with rheumatic mitral valve disease in sinus rhythm.

Authors:  Hyun-Jin Kim; Goo-Yeong Cho; Yong-Jin Kim; Hyung-Kwan Kim; Seung-Pyo Lee; Hack-Lyoung Kim; Jin Joo Park; Yeonyee E Yoon; Joo-Hee Zo; Dae-Won Sohn
Journal:  Int J Cardiovasc Imaging       Date:  2015-02-10       Impact factor: 2.357

3.  The N-terminal pro-brain-type natriuretic peptide based short-term prognosis in patients with acute pulmonary embolism according to renal function.

Authors:  T M Berghaus; W Behr; W von Scheidt; M Schwaiblmair
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

Review 4.  New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.

Authors:  Birgitte Klindt Poulsen; Erik Lerkevang Grove; Steen Elkjaer Husted
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

Review 5.  Standard or extended-duration prophylaxis in medical patients? A review of the evidence.

Authors:  J E Stark; W J Smith
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

Review 6.  Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.

Authors:  Meyer Michel Samama
Journal:  Drugs Aging       Date:  2011-03-01       Impact factor: 3.923

Review 7.  Thrombosis and anticoagulation in the setting of renal or liver disease.

Authors:  Christine Ribic; Mark Crowther
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 8.  Low-molecular-weight heparin in patients with chronic renal insufficiency.

Authors:  Wendy Lim
Journal:  Intern Emerg Med       Date:  2008-06-18       Impact factor: 3.397

Review 9.  Using low molecular weight heparin in special patient populations.

Authors:  Wendy Lim
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

10.  Severe bleeding secondary to misuse of fondaparinux: a case report.

Authors:  Hubert Nielly; Aurore Bousquet; Patrick Le Garlantezec; Eric Perrier; Xavier Bohand
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.